Publications scientifiques sur les diagnostics non invasifs BioPredictive
Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.
21/435
Résultats pour
“polymerase inhibitor”
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
### Background & Aims Patients with chronic hepatitis C virus infection and advanced fibrosis…
-
Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Review
It is estimated that hepatitis C virus (HCV) infects chronically about 160…
-
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
### Background In the UNITY-3 study, 96% sustained virologic response (SVR12) rate…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients.
### Objective Liver biopsy, the gold standard for assessing hepatitis C virus (HCV…
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C.
Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
…reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor drugs were the…
-
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
In chronic hepatitis C, biopsy is the gold standard for assessment of…
-
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
As an alternative to liver biopsy, an index of five biochemical markers…
-
Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up.
### Background Due to common routes of transmission, HIV and HBV are frequently…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
### Introduction Long-term tenofovir disoproxil fumarate (TDF) use has been associated with…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.